Skip to content

AbbVie

Recent events

Recent events tied to this brand in public sources.

Back to profile48 entries · Page 3 of 3

  1. 2020

    Synlogic and AbbVie terminate IBD collaboration

    Synlogic announced the termination of its collaboration with AbbVie on Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease. Synlogic regains the rights to develop the programs and to partner them.

  2. 2020

    Thomas C. Freyman elected to AbbVie board

    AbbVie’s board elected Thomas C. Freyman, Abbott’s retired executive vice president and chief financial officer, to join the board in connection with the Allergan deal closing.

  3. 2020

    AbbVie completes acquisition of Allergan

    AbbVie announced that it had completed its acquisition of Allergan; the transaction had received the required government regulatory approvals and approval from the High Court of Ireland.

  4. 2020

    Nitrome closes $38 million Series A financing

    Nitrome Biosciences announced that it had closed a $38 million Series A financing co-led by Sofinnova Partners and AbbVie Ventures, with participation from other investors. The financing is intended to advance its Parkinson's disease program and explore other age-related disease indications.

  5. 2019

    Alkem Laboratories agrees to acquire Dronabinol-related assets from AbbVie

    Alkem Laboratories entered into an asset purchase agreement with AbbVie for certain assets related to the active pharmaceutical ingredient Dronabinol, including Marinol-related intellectual property and regulatory assets. The stated acquisition cost is USD 10 million plus working capital adjustments on closing.

  6. 2019

    Drugmakers agree to reduce prices of some medicines in China

    Chinese regulators said pharmaceutical companies, including Roche and Novartis, agreed to reduce the China prices of some newer medicines by an average of 61% to enter the national medical insurance reimbursement list.

  7. 2019

    AbbVie updates 2019 earnings guidance

    AbbVie updated its full-year 2019 GAAP diluted EPS guidance range to $5.08–$5.10 and raised its adjusted diluted EPS guidance range to $8.90–$8.92.

  8. 2019

    AbbVie and Cystic Fibrosis Foundation announce licensing collaboration

    AbbVie and the Cystic Fibrosis Foundation announced a strategic collaboration under which AbbVie will develop a CFTR potentiator compound licensed from the Foundation and advance it into clinical development for potential use in combination treatments for cystic fibrosis.